Disruption of IFN-γ - Mediated antiviral activity in neurons: The role of cannabinoids

Viral Immunology

Volumn 21, Issue 2, 2008, Pages 141-152

  Herrera, R Antonio ^a   Oved, Joseph H ^a   Reiss, Carol Shoshkes ^a,b,c  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CALCIUM; CANNABINOID; CANNABINOID 1 RECEPTOR; GAMMA INTERFERON; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOCYTOCHEMISTRY; MOUSE; NERVE CELL; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS VIRUS; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; CANNABINOIDS; CELL LINE; CELL SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE II; MICE; NEURONS; NITRIC OXIDE; PLAQUE ASSAY; RECEPTORS, CANNABINOID; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

VESICULAR STOMATITIS VIRUS;

EID: 45749113356     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0109     Document Type: Conference Paper

References (79)

1. Adler H, Beland JL, Del-Pan NC, Kobzik L, Brewer JP, Martin TR, and Rimm IJ: Suppression of herpes simplex virus type 1a(HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2). J Exp Med 1997;185:1533-1540.
2. Ahn DK, Choi HS, Yeo SP, et al.: Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoidinduced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain. 2007;132:23-32.
3. Akaike T, and Maeda H: Nitric oxide and virus infection. Immunology 2000;101:300-308.
4. Alger BE: Endocannabinoid identification in the brain: Studies of breakdown lead to breakthrough, and there may be NO hope. Sci. STKE 2005;e51.
5. Andersson M, Usiello A, Borgkvist A, et al.: Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 2005;25:8432-8438.
6. Bahr BA, Karanian DA, Makanji SS, and Makriyannis A: Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs 2006;15:351-365.
7. Belayev L, Busto R, Watson BD, and Ginsberg MD: Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study. Brain Res 1995;702:266-270.
8. Bi Z, and Reiss CS: Inhibition of vesicular stomatitis virus infection by nitric oxide. J Virol 1995;69:2208-2213.
9. Bredt DS, and Snyder SH: Nitric oxide: A physiologic messenger molecule. Ann Rev Biochem 1994;63:175-195.
10. Burstein S: PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 2005;77:1674-1684.
11. Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, and Munson AE: Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med 1986; 182:181-186.
12. Chaperon F, and Thiebot MH: Beneficial effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13:243-281.
13. Chesler DA, Dodard C, Lee GY, Levy DE, and Reiss CS: Interferon-gamma- induced inhibition of neuronal vesicular stomatitis virus infection is STAT1 dependent. J Neurovirol 2004;10:57-63.
14. Chesler DA, McCutcheon JA, and Reiss CS: Posttranscriptional regulation of neuronal nitric oxide synthase expression by IFN-gamma. J Interferon Cytokine Res 2004;24:141-149.
15. Chesler DA, Munoz-Jordan JL, Donelan N, Garcia-Sastre A, and Reiss CS: PKR is not required for interferon-gamma inhibition of VSV replication in neurons. Viral Immunol 2003;16:87-96.
16. Chesler DA, and Reiss CS. IL-12, while beneficial, is not essential for the host response to VSV encephalitis. J Neuroimmunol 2002;131:92-97.
17. Chesler DA, and Reiss CS: The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002;13:441-454.
18. Coleman JW: Nitric oxide in immunity and inflammation. Int Immunopharmacol 2001;1:1397-1406.
19. Croxford JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202.
20. Croxford JL, and Miller SD: Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212. J Clin Invest 2003;111:1231-1240.
21. Dawson TM, Zhang J, Dawson VL, and Snyder SH: Nitric oxide: cellular regulation and neuronal injury. Prog Brain Res 1994;103:365-369.
22. Diaz-Laviada I, and Ruiz-Llorente L: Signal transduction activated by cannabinoid receptors. Mini Rev Med Chem 2005;5:619-630.
23. Ehrhart J, Obregon D, Mori T, et al.: Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2007;12:2-29.
24. Eljaschewitsch E, Witting A, Mawrin C, et al.: The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49:67-79.
25. Fernandez-Lopez D, Martinez-Org E, Nunez J, Romero P, Lorenzo M, Moro A, and Lizasoain I: Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006;60:169-173.
26. Fisyunov, A., Tsintsadze V, Min R, Burnashev N, and Lozovaya N: Cannabinoids modulate the P-type high-voltage-activated calcium currents in Purkinje neurons. J Neurophysiol 2006;96:1267-1277.
27. González S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor agonist, in a rat model of Parkinson's disease. Brain Res 2006;209-9:1073-1074.
28. Gilbert GL, Kim HJ, Waataja JJ, and Thayer SA: Delta(9)- Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007;1128:61-69.
29. Gomez RM, Yep A, Schattner M, and Berria MI: Junin virus-induced astrocytosis is impaired by iNOS inhibition. J Med Virol 2003;69:145-149.
30. Gomez R, Navarro M, Ferrer B, et al.: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-9617.
31. Hooper DC, Kean RB, Scott GS, et al.: The central nervous system inflammatory response to neurotropic virus infection is peroxynitrite dependent. J Immunol 2001;167:3470-3477.
32. Hu J, and El-Fakahany EE: Intricate regulation of nitric oxide synthesis in neurons. Cellular Signal 1996;8:185-189.
33. Huneycutt BS, Bi Z, Aoki CJ, and Reiss CS: Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 1993;67:6698-6706.
34. Huneycutt BS, Plakhov IV, Shusterman Z, Bartido SM, Huang A, Reiss CS, and Aoki C: Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res 1994;635:81-95.
35. Ibrahim MM, Rude ML, Stagg NJ, et al.: CB2 cannabinoid receptor mediation of antinociception. Pain 2006;122: 36-42.
36. Ireland DD, Palian BM, and Reiss CS: Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis. Viral Immunol 2005; 18:397-402.
37. Ireland DD, and Reiss CS: Expression of IL-12 receptor by neurons. Viral Immunol. 2004;17:411-422.
38. Jackson SJ, Diemel LT, Pryce G, and Baker D: Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005;233:21-25.
39. Jaffrey SR, and Snyder SH: PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science 1996;274: 774-777.
40. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, and MacMicking JD: Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993;261:1445-1448.
41. Kim SH, Won SJ, Mao XO, Ledent C, Jin K, and Greenberg DA: Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 2006;319:150-154.
42. Kim SH, Won SJ, Mao XO, Jin K, and Greenberg DA: Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 2006;69:691-696.
43. Komatsu T, Bi Z, and Reiss CS: Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J Neuroimmunol 1996;68:101-108.
44. Komatsu T, Ireland DD, Chen N, and Reiss CS: Neuronal expression of NOS-1 is required for host recovery from viral encephalitis. Virology 1999;258:389-395.
45. Kushmerick C, Price GD, Taschenberger H, et al.: Retroinhibition of presynaptic Ca2+ currents by endocannabinoids released via postsynaptic mGluR activation at a calyx synapse. J Neurosci 2004;24:5955-5965.
46. Lane TE, Fox HS, and Buchmeier MJ: Inhibition of nitric oxide synthase-2 reduces the severity of mouse hepatitis virus-induced demyelination: implications for NOS2/NO regulation of chemokine expression and inflammation. J Neurovirol 1999;5:48-54.
47. Lukas SE, Mendelson JH, and Benedikt R: Electroencephalographic correlates of marihuana-induced euphoria. Drug Alcohol Depend 1995;37:131-140.
48. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, and Dittel BN: Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005;95:437-445.
49. 1 on neurons and CB2 on autoreactive T cells. Nat Med 2007;13:492-497.
50. 1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:84-88.
51. Martinez-Orgado B, Fernandez-Frutos R, Gonzalez R, Romero E, Uriguen L, Romero J, and Viveros MP: Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Mol Brain Res 2003;114:132-139.
52. Mestre L, Correa F, Docagne F, Clemente D, and Guaza C: The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 2006;72:869-880.
53. Mestre L, Correa F, Revalo-Martin A, et al.: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005;92: 1327-1339.
54. Mishkin EM, and Cabral GA. delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 1985;66(Pt 12):2539-2549.
55. Murray RM, Morrison PD, Henquet C, and Di FM: Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007;8:885-895.
56. Naef M, Curatolo M, Petersen-Felix S, Rendt-Nielsen L, Zbinden A, and Brenneisen R: The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88.
57. Nathan C, and Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 1994;78:915-918.
58. Noe SN, Nyland SB, Ugen K, Friedman H, and Klein TW: Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol 1998;437:223-229.
59. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, and Randall MD: Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem. Biophys. Res. Commun. 2005;337:824-831.
60. Pacher P, Batkai S, and Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
61. Pan X, Ikeda SR, and Lewis DL: Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 1996;49:707-714.
62. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, and Shohami E: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527-531.
63. Plakhov IV, Arlund EE, Aoki C, and Reiss CS: The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 1995:209:257-262.
64. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, and Malan Jr. TP: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003;99:955-960.
65. Ramirez BG, Blazquez C, del Gomez PT, Guzman M, and de Ceballos ML: Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904-1913.
66. Rawls SM, Tallarida RJ, Gray AM, Geller EB, and Adler MW: L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl- carbonyl)-6 H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J Pharmacol Exp Ther 308:780-786.
67. Reiss CS, and Komatsu T: Does nitric oxide play a critical role in viral infections? J Virol 1998;72:4547-4551.
68. Rivest S: Cannabinoids in microglia: a new trick for immune surveillance and neuroprotection. Neuron 2006;49: 4-8.
69. Sarne Y, and Mechoulam R: Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 2005;4:677-684.
70. Shackelford DA, and Yeh RY: Activation of extracellular signal-regulated kinases (ERK) during reperfusion of ischemic spinal cord. Mol Brain Res 2003;115:173-186.
71. Shohami E, Novikov M, and Mechoulam R: A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 1993;10:109-119.
72. Sun Y, Alexander SP, Kendall DA, and Bennett AJ: Cannabinoids and PPARalpha signalling. Biochem Soc Trans 2006;34:1095-1097.
73. Ullrich O, Merker K, Timm J, and Tauber S: Immune control by endocannabinoids - New mechanisms of neuroprotection? J Neuroimmunol. 2007;184(1-2):127-35.
74. Ullrich O, Schneider-Stock R, and Zipp F: Cell-cell communication by endocannabinoids during immune surveillance of the central nervous system. Results Probl Cell Differ 2006;43:281-305.
75. Wang KS, Frank DA, and Ritz J: Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 2000;95:3183-3190.
76. Wenger T, and Moldrich G: The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot Essent Fatty Acids 2002;66:301-307.
77. Wilson RI, Kunos G, and Nicoll RA: Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001;31:453-462.
78. Yang J, Dennison NN, and Reiss CS: PIN: a novel protein involved in IFN-g accumulation of NOS-1 in neurons. J DNA and Cell Bio 2008;27(1):9-17.
79. Yang J, Tugal D, and Reiss CS: The role of the proteasome-ubiquitin pathway in regulation of the IFN-gamma mediated anti-VSV response in neurons. J Neuroimmunol 2006;181:34-45.